Modulators of peroxisome proliferator activated receptors

US6610696B2 · kind B2 · utility

Assignees

• ELI LILLY AND COMPANY · US
• Ligand Pharmaceuticals Incorporated · US

Inventors

• Dawn Brooks · Indianapolis, US
• Christopher J. Rito · Mooresville, US
• Anthony John Shuker · Indianapolis, US
• Samuel James Dominianni · Indianapolis, US
• Alan M. Warshawsky · Cincinnati, US
• Lynn Stacy Gossett · Indianapolis, US
• Donald P. Matthews · Sharonville, US
• David A. Hay · Indianapolis, US
• Robert Ardecky · Village of La Jolla, US
• Pierre-Yves Michellys · San Marcos, US
• John Tyhonas · San Diego, US

Key dates

• Filing date: Apr 11, 2002
• Grant date: Aug 26, 2003
• Expiry date: Apr 11, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D277/24
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: In Structural Formula I, n is 2, 3, or 4; V is O or S; W is O, S, or SO2; R1 is H, a C1-C4 alkyl, phenyl or trifluoromethyl; R2 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, a cycloalkyl, or together with the phenyl to which they are bound form naphthyl or 1,2,3,4-tetrahydronaphthyl; R3 are each, independently, H, a C1-C6 alkyl, an aryl-C1-C6 alkyl, a cycloalkyl-C1-C4 alkyl, an aryl, or a cycloalkyl; R4 are each, independently, H, a C1-C4 alkyl, an aryl, or benzyl; R5 are each, independently, H, a substituted or unsubstituted aryl or a heteroaryl, provided that at least one R5 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; and R6 is H, a C1-C4 alkyl, or an aminoalkyl.